Maxwell Colleen J, Campitelli Michael A, Hogan David B, Diong Christina, Austin Peter C, Amuah Joseph E, Lapane Kate, Seitz Dallas P, Gill Sudeep S, Gruneir Andrea, Wodchis Walter P, Bronskill Susan E
Schools of Pharmacy and Public Health and Health Systems, University of Waterloo, Waterloo, Canada.
Institute for Clinical Evaluative Sciences, Toronto, Canada.
Pharmacoepidemiol Drug Saf. 2018 Mar;27(3):289-298. doi: 10.1002/pds.4385. Epub 2018 Jan 10.
To examine the association between new antipsychotic use and mortality over 6 months among community-based older adults with cognitive impairment, and variation in risk by frailty and sex.
We conducted a retrospective cohort study of older (aged 66+) home care clients in Ontario, Canada, using linked administrative health and clinical databases. Included were clients with dementia and/or significant cognitive impairment assessed during April 2008 to March 2013. Frailty was defined using a validated 72-item index. Exposed were those newly dispensed an antipsychotic in the 6 months post cohort entry, with no such claims in the year prior to drug index date. Two-stage matching defined unexposed clients and their index date (matching on age, sex, frailty, assessment year, and propensity score). Outcome was time to death following index date. Cause-specific hazards models were used, and number needed to harm at 6 months was estimated from cumulative incidence function curves.
Among 4955 matched exposed-unexposed pairs, new antipsychotic users showed a significantly increased hazard of mortality at 1, 3, and 6 months relative to unexposed, with the highest risk observed in the first month (hazard ratio [HR] = 2.08 [95% CI, 1.79-2.43]). At 1 month, risk was significantly higher for robust (HR = 3.72 [95% CI, 2.45-5.66]) vs frail (HR = 1.74 [95% CI, 1.40-2.17], P = .002) clients. The number needed to harm was 22.7 and did not vary by frailty but was lower for men (14.9) than for women (35.0).
Risk of antipsychotic-associated mortality was highest in the first month following exposure, varied significantly by client frailty, and was greater among men than among women.
研究社区认知功能受损的老年人在6个月内使用新型抗精神病药物与死亡率之间的关联,以及虚弱程度和性别对风险的影响。
我们利用加拿大安大略省行政卫生与临床数据库的关联数据,对66岁及以上的居家护理老年患者进行了一项回顾性队列研究。纳入2008年4月至2013年3月期间评估为患有痴呆症和/或严重认知功能障碍的患者。使用经过验证的72项指标定义虚弱程度。暴露组为队列入组后6个月内新使用抗精神病药物的患者,在药物索引日期前一年无此类用药记录。通过两阶段匹配确定未暴露组患者及其索引日期(根据年龄、性别、虚弱程度、评估年份和倾向得分进行匹配)。结局指标为索引日期后的死亡时间。采用特定病因风险模型,并根据累积发病率函数曲线估计6个月时的伤害所需人数。
在4955对匹配的暴露组与非暴露组中,新型抗精神病药物使用者在1个月、3个月和6个月时的死亡风险相对于未暴露组显著增加,第一个月风险最高(风险比[HR]=2.08[95%CI,1.79-2.43])。在1个月时,强健患者(HR=3.72[95%CI,2.45-5.66])的风险显著高于虚弱患者(HR=1.74[95%CI,1.40-2.17],P=0.002)。伤害所需人数为22.7,不因虚弱程度而异,但男性(14.9)低于女性(35.0)。
抗精神病药物相关死亡风险在暴露后的第一个月最高,因患者虚弱程度而异,且男性高于女性。